Jason S. Throne J.D., Esq.
Net Worth
Last updated:
What is Jason S. Throne J.D., Esq. net worth?
The estimated net worth of Mr. Jason S. Throne J.D., Esq. is at least $3,673,840 as of 27 Jun 2024. He owns shares worth $11,790 as insider, has earned $1,534,250 from insider trading and has received compensation worth at least $2,127,800 in IDEAYA Biosciences, Inc..
What is the salary of Jason S. Throne J.D., Esq.?
Mr. Jason S. Throne J.D., Esq. salary is $425,560 per year as Senior Vice President, Gen. Counsel & Company Sec. in IDEAYA Biosciences, Inc..
How old is Jason S. Throne J.D., Esq.?
Mr. Jason S. Throne J.D., Esq. is 53 years old, born in 1972.
What stocks does Jason S. Throne J.D., Esq. currently own?
As insider, Mr. Jason S. Throne J.D., Esq. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
IDEAYA Biosciences, Inc. (IDYA) | Senior Vice President, Gen. Counsel & Company Sec. | 500 | $23.58 | $11,790 |
What does IDEAYA Biosciences, Inc. do?
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Jason S. Throne J.D., Esq. insider trading
IDEAYA Biosciences, Inc.
Mr. Jason S. Throne J.D., Esq. has made 17 insider trades between 2020-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 47,060 units of IDYA stock on 27 Jun 2024. As of 27 Jun 2024 he still owns at least 500 units of IDYA stock.
IDEAYA Biosciences key executives
IDEAYA Biosciences, Inc. executives and other stock owners filed with the SEC:
- Mr. Jason S. Throne J.D., Esq. (53) Senior Vice President, Gen. Counsel & Company Sec.
- Mr. Paul A. Stone (61) Senior Vice President, Chief Financial Officer & Principal Accounting Officer
- Mr. Yujiro S. Hata (51) Co-Founder, Chief Executive Officer, Pres & Director